ZGN 1061

Drug Profile

ZGN 1061

Alternative Names: ZGN-1061; ZGN1601

Latest Information Update: 25 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Zafgen
  • Class Obesity therapies; Small molecules
  • Mechanism of Action Methionine aminopeptidase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Type 2 diabetes mellitus
  • Phase I Obesity

Most Recent Events

  • 12 Sep 2017 Phase-II clinical trials in Type-2 diabetes mellitus in New Zealand and Australia (SC) (NCT03254368)
  • 12 Sep 2017 Pharmacodynamics data from a preclinical study in Type 2 diabetes mellitus presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes (EASD-2017)
  • 08 Aug 2017 Zafgen plans a phase II trial for Type 2 diabetes mellitus in Australia and New Zealand in the third quarter of 2017 (SC) (NCT03254368)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top